Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 28;S1556-0864(20)30331-2.
doi: 10.1016/j.jtho.2020.04.016. Online ahead of print.

Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic

Affiliations
Free PMC article

Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic

Sameera Kumar et al. J Thorac Oncol. .
Free PMC article

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is currently accelerating. Patients with locally advanced NSCLC (LA-NSCLC) may require treatment in locations where resources are limited, and the prevalence of infection is high. Patients with LA-NSCLC frequently present with comorbidities that increase the risk of severe morbidity and mortality from COVID-19. These risks may be further increased by treatments for LA-NSCLC. Although guiding data is scarce, we present an expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus of alternative strategies for the treatment of LA-NSCLC during a pandemic. The overarching goals of these approaches are the following: (1) reduce the number of visits to a health care facility, (2) reduce the risk of exposure to severe acute respiratory syndrome-coronavirus-2, (3) attenuate the immunocompromising effects of lung cancer therapies, and (4) provide effective oncologic therapy. Patients with resectable disease can be treated with definitive nonoperative management if surgical resources are limited or the risks of perioperative care are high. Nonoperative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules that may or may not affect long-term outcomes in an era in which immunotherapy is available. The order of treatments may be on the basis of patient factors and clinical resources. Whenever radiation therapy is delivered without concurrent chemotherapy, hypofractionated schedules are appropriate. For patients who are confirmed to have COVID-19, usually, cancer therapies may be withheld until symptoms have resolved with negative viral test results. The risk of severe treatment-related morbidity and mortality is increased for patients undergoing treatment for LA-NSCLC during the COVID-19 pandemic. Adapting alternative treatment strategies as quickly as possible may save lives and should be implemented through communication with the multidisciplinary cancer team.

Keywords: COVID; Locally advanced; Non–small cell lung cancer; SARS–CoV-2.

Similar articles

See all similar articles

References

    1. World Health Organization 2020 Coronavirus disease 2019 (COVID-19) situation report–85. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200414-sitrep-85-covid-19.pdf?sfvrsn=7b8629bb_2
    1. American Society for Radiation Oncology (ASTRO) 2020 COVID-19 resources FAQs. https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information/COVID-19-FAQs
    1. American Society of Clinical Oncology ASCO coronavirus resources. https://www.asco.org/asco-coronavirus-information
    1. Guckenberger M, Belka C, Bezjak A, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement [e-pub ahead of print]. Radiother Oncol. https://doi.org/10.1016/j.radonc.2020.04.001, accessed April 6, 2020. - DOI
    1. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region - case series [e-pub ahead of print]. N Engl J Med. https://doi.org/10.1056/NEJMoa2004500, accessed April 6, 2020. - DOI

LinkOut - more resources

Feedback